Walmart just posted its weakest U.S. sales growth in six years, and investors punished the stock with one of its worst single-day drops in more than four years.
Quick Take
- U.S. comparable sales rose just 2.6% last quarter, the slowest pace since 2020.
- Shares fell as much as 9% even though total revenue jumped 4.8% to $177.4 billion.
- Walmart blamed part of the slowdown on new pharmacy price caps that hit health-and-wellness sales.
- Strip out that pricing effect, and core U.S. sales actually grew a healthier 3.4%.
- Online sales kept climbing worldwide, up 25%, showing the slowdown wasn’t everywhere.
Slowest Sales Growth Since the Pandemic
Walmart’s second-quarter earnings release showed U.S. comparable sales grew 2.6%, the company’s slowest pace in more than six years. Comparable sales measure how much money existing stores and clubs bring in compared to the same period a year earlier. Multiple news outlets confirmed this was Walmart’s weakest showing since 2020, a striking number for the country’s largest retailer.
The slowdown stood out because Walmart has spent years outpacing rivals as shoppers hunted for lower prices. A dip this size, even a modest one, signals something changed inside the business or in how customers are spending their money at the checkout line.
Wall Street Reacts With a Sharp Sell-Off
Investors expected better. Analysts tracked by Yahoo Finance had predicted 3.1% comparable-sales growth, while a separate estimate from data firm LSEG put the bar even higher at 3.8%. When Walmart came in below both marks, shares tumbled between 6% and 9% depending on the trading session, according to Reuters.
The sell-off reflected more than disappointment over one number. Walmart is widely treated as a barometer for how everyday American households are feeling about their finances, so a miss at the register can ripple through how investors view the broader economy.
Pharmacy Price Caps Take a Bite Out of Sales
Company executives pointed to a specific culprit: new pharmacy pricing rules known as Maximum Fair Price, which cut into health-and-wellness sales. These price caps limit what retailers can charge for certain prescription drugs, which lowers revenue even if the same number of customers walk through the door.
When Walmart stripped out that pricing headwind, the picture looked much stronger. Core U.S. comparable sales rose 3.4% instead of 2.6%, according to reporting on the earnings release. That gap suggests regulation, not just weaker shopper demand, played a real role in the disappointing headline number.
Strong Revenue and Online Growth Tell a Different Story
Walmart’s overall results were not weak across the board. Total revenue climbed 4.8% to $177.4 billion, and the company’s earnings call transcript said sales rose 5.6% in constant currency terms. Global e-commerce growth hit 25%, showing shoppers kept moving purchases online even as in-store comparable sales cooled.
$WMT Walmart posted its worst single-day drop in more than four years.
Q2 US comparable sales grew 2.6% versus the 3.5% FactSet consensus. Q3 fiscal 2027 EPS guidance and full-year EPS guidance both came in below Wall Street expectations, offsetting Walmart's strong revenue…
— Finance Spot (@financespotnews) August 21, 2026
That mixed picture matters for how Americans should read this report. A single comparable-sales number grabbed headlines and triggered a stock sell-off, but Walmart’s broader business, including its fast-growing digital and advertising operations, kept expanding at a healthy clip during the same three months.
What This Means for Shoppers and the Economy
Walmart’s report lands at a time when both conservative and liberal households are watching grocery bills and prescription costs closely. Whether the slowdown reflects cautious consumers pulling back or a pricing rule squeezing margins, the outcome feels the same at checkout: a company built on low prices found it harder to keep growing this quarter.
Sources:
feedpress.me, nypost.com, whtc.com, investing.com, finance.yahoo.com, reuters.com, stock.walmart.com